Business
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule

About this update from Enanta Pharmaceuticals, Inc.
WATERTOWN, Mass. --(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that members of management will participate in a fireside chat at The Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 10:45 a.m. ET in Miami Beach, FL. A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com . A replay of the webcast will be available following the presentation and will be archived for at least 30 days. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® ( U.S. ) and MAVIRET® (ex- U.S. ) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. View source version on businesswire.com : https://www.businesswire.com/news/home/20260303831297/en/ Media and Investors Contact: Jennifer Viera 617-744-3848 [email protected] Source: Enanta Pharmaceuticals, Inc.
View stock analysis, news, and events for Enanta Pharmaceuticals, Inc.